Tyra Biosciences, Inc. — Director's Dealing 2021

Sep 21, 2021

SEC Form 4/A — Form 4/A

Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-09-17

Reporting Person: Kjellson Nina S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-17	Common Stock	C	3936595	—	Acquired	3936595	Indirect
2021-09-17	Common Stock	C	473396	—	Acquired	473396	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-17	Series A Preferred Stock	$	C	1333334	Disposed		Common Stock (3463201)	Indirect
2021-09-17	Series B Preferred Stock	$	C	182257	Disposed		Common Stock (473394)	Indirect
2021-09-17	Series B Preferred Stock	$	C	182258	Disposed		Common Stock (473396)	Indirect

Footnotes

F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

F3: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.